Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Journal Article
| Authors: | Morgensztern, D.; Campo, M. J.; Dahlberg, S. E.; Doebele, R. C.; Garon, E.; Gerber, D. E.; Goldberg, S. B.; Hammerman, P. S.; Heist, R. S.; Hensing, T.; Horn, L.; Ramalingam, S. S.; Rudin, C. M.; Salgia, R.; Sequist, L. V.; Shaw, A. T.; Simon, G. R.; Somaiah, N.; Spigel, D. R.; Wrangle, J.; Johnson, D.; Herbst, R. S.; Bunn, P.; Govindan, R. |
| Article Title: | Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 |
| Abstract: | There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy. |
| Keywords: | signal transduction; unclassified drug; clinical feature; review; sunitinib; advanced cancer; molecular genetics; antineoplastic agent; cancer incidence; unindexed drug; cancer immunotherapy; gene amplification; lung cancer; lung adenocarcinoma; protein processing; immunotherapy; early cancer; epigenetics; cancer immunization; fusion gene; vandetanib; genomics; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; nomenclature; mucin 1; lung carcinogenesis; point mutation; trastuzumab; lethality; non-small-cell lung cancer; mutant; neratinib; targeted therapies; small cell lung cancer; non small cell lung cancer; b raf kinase inhibitor; molecularly targeted therapy; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); multicenter study (topic); crizotinib; cabozantinib; afatinib; dacomitinib; ponatinib; alisertib; belagenpumatucel l; foretinib; lenvatinib; human; priority journal; ceritinib; alectinib; [2 [[5 chloro 2 [[4 [4 (dimethylamino) 1 piperidinyl] 2 methoxyphenyl]amino] 4 pyrimidinyl]amino]phenyl]dimethylphosphine oxide; squamous cell lung carcinoma; 2 allyl 1 [6 (1 hydroxy 1 methylethyl) 2 pyridinyl] 6 [4 (4 methyl 1 piperazinyl)anilino] 1h pyrazolo[3,4 d]pyrimidin 3(2h) one; abemaciclib; duligotuzumab; loxo 101; mm 111; plx 7486; seribantumab; tergenpumatucel l; volasertib |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 10 |
| Issue: | 1 Suppl.1 |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-01-01 |
| Start Page: | S1 |
| End Page: | S63 |
| Language: | English |
| DOI: | 10.1097/jto.0000000000000405 |
| PROVIDER: | scopus |
| PUBMED: | 25535693 |
| PMCID: | PMC4346098 |
| DOI/URL: | |
| Notes: | Export Date: 2 February 2015 -- Source: Scopus |
